Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders, has received approval from the U.S. Food and Drug Administration for its Investigational New Drug application for Lucid-MS, the company’s lead compound for multiple sclerosis. The FDA’s decision, announced on September 25, 2026, clears the path for Phase 2 clinical testing and represents a significant milestone for a drug that could offer a new mechanism of action in a field where most existing therapies target the immune system.
The IND approval allows Quantum BioPharma to begin recruiting patients and administering Lucid-MS in a controlled clinical setting. This step is critical because it moves the drug from earlier-stage testing into a larger patient population, where researchers can more rigorously assess both safety and efficacy. The ability to start Phase 2 testing means the company can now generate data that will inform the design of later-stage trials and, ultimately, regulatory submissions.
What sets Lucid-MS apart from most existing MS therapies is its mechanism. While many approved treatments for multiple sclerosis work by modulating or suppressing the immune system to reduce relapses, Lucid-MS takes a different approach. According to the company, this novel mechanism could potentially address the underlying disease process in a way that existing therapies do not. That distinction is important because multiple sclerosis is a chronic, often progressive disease that affects the central nervous system, and patients need options that can slow or halt disability accumulation.
Lucid-MS previously completed Phase 1 clinical trials, where it showed a favorable safety profile and was well tolerated. Those results are a key foundation for the Phase 2 program, as safety is a primary concern for any new therapy, especially one intended for long-term use in a chronic condition. The transition to Phase 2 testing indicates that the drug has passed the initial safety hurdle and can now be evaluated in patients with multiple sclerosis.
The FDA’s green light is also a validation of Quantum BioPharma’s development strategy. The company is trading on the Nasdaq under the ticker QNTM, and the announcement could raise its profile among investors and potential partners. For a smaller biopharmaceutical company, achieving an IND approval and advancing a lead candidate into Phase 2 is a substantial de-risking event. It demonstrates that the company can navigate the regulatory process and that its preclinical and Phase 1 data were sufficient to satisfy the FDA’s requirements to proceed.
Investors and other interested parties can find more details about the approval and the company’s plans in the original release available at www.newmediawire.com. The news was initially distributed through NEWMEDIAWIRE, and additional information about the company is available at Quantum BioPharma (NASDAQ: QNTM). The latest updates relating to QNTM can be found in the company’s newsroom at https://ibn.fm/QNTM.
As with any clinical-stage biopharmaceutical company, Quantum BioPharma faces risks and uncertainties. Forward-looking statements in the original release note that actual results may differ materially from expectations due to factors beyond management’s control, including risks detailed in the company’s SEC filings. The Phase 2 trial will be closely watched, as its outcome will determine whether Lucid-MS can advance further toward becoming a new treatment option for multiple sclerosis patients.
